Last updated: February 27, 2026
What is the Drug Identified by NDC 00173-0720?
NDC 00173-0720 refers to Botulinum Toxin Type A (OnabotulinumtoxinA), marketed as Botox. It is approved for various therapeutic and aesthetic indications, including muscle spasticity, chronic migraines, hyperhidrosis, and cosmetic reduction of facial wrinkles.
Market Overview
Market Size and Demand
The global botulinum toxin market was valued at approximately USD 6.7 billion in 2022 and is projected to reach USD 10 billion by 2030, with a compound annual growth rate (CAGR) of 5.8% (Fortune Business Insights, 2023). Key drivers include expanding therapeutic applications and aesthetic procedures' rising popularity.
Geographic Breakdown
North America dominates the market with about 60% share, driven by high healthcare provider adoption, reimbursement frameworks, and consumer acceptance. Europe holds approximately 25%, and Asia-Pacific is the fastest-growing segment, with a CAGR of 7.2% due to increased healthcare infrastructure investments and growing awareness.
Competitive Landscape
Major players include:
- AbbVie Inc. (Botox, Dysport)
- Ipsen Group (Dysport)
- Hugel, Inc. (Neuronox)
- Medytox Inc. (Neuronox)
- Revance Therapeutics, Inc. (RHA Collection)
Market share distribution favors AbbVie, which commands an estimated 80% of the U.S. Botox market. New entrants focus on biosimilars, targeting market consolidation and price competition.
Regulatory and Reimbursement Environment
- FDA Approval: Botox received FDA approval in 1989 for strabismus and blepharospasm, expanding to therapeutic and cosmetic indications.
- Pricing Regulation: The U.S. reimbursement structure varies mainly through private insurers and Medicare, with prices negotiated or set administratively.
- International Markets: Regulatory pathways differ; some countries follow the European Medicines Agency (EMA) or other regional bodies. Market approval timelines impact product accessibility.
Current Pricing Landscape
U.S. Pricing
Average wholesale prices (AWP) for Botox vary:
| Indication |
Approximate Price per Unit |
Typical Dose Range |
Comments |
| Aesthetic (cosmetic wrinkles) |
USD 15-19 |
20-60 units per session |
Pricing depends on provider, location |
| Chronic migraine |
USD 15-19 |
155 units per session |
Dose administered every 12 weeks |
| Spasticity |
USD 15-19 |
200-400 units |
Dose varies with severity |
Treatment Cost Estimates
For aesthetic uses, a typical treatment of 40 units costs USD 600-760. For chronic migraines, total treatment costs can range from USD 2,500 to USD 4,000 per session.
Biosimilar Impact
Biosimilar entries by companies like Medytox and Revance aim to reduce market prices by 20-30%, impacting overall pricing and revenue for originator products.
Price Projections (2023–2030)
| Year |
Expected Price per Unit (USD) |
Drivers/Notes |
| 2023 |
USD 15-19 |
Current market stabilization |
| 2025 |
USD 13-17 |
Biosimilar competition increases |
| 2027 |
USD 12-15 |
Further biosimilar entry, negotiated pricing |
| 2030 |
USD 10-13 |
Mature biosimilar market, price-driven volume |
The downward trend reflects generic/biosimilar competition, regulatory pressures, and reimbursement negotiations. Overall treatment costs may decrease by 25-35% from 2023 to 2030.
Key Market Dynamics
- Innovation: New formulations and delivery systems (e.g., cryo-electrolysis, next-generation botulinum toxins) could influence pricing.
- Regulatory Changes: Approvals for new indications and biosimilar pathways may accelerate price reductions.
- Market Penetration: Increasing use in indications like depression and new aesthetic segments may sustain revenue streams even as per-unit prices decline.
- Reimbursement Policy: Evolving policies, particularly in the U.S., could either pressure prices downward or sustain premium pricing based on perceived value.
Summary
NDC 00173-0720 (Botulinum Toxin Type A) remains a dominant product in both therapeutic and aesthetic markets. Its market is expected to grow driven by new indications and expanding geographic reach. Price per unit is projected to decline steadily due to biosimilar competition, with a notable decrease of approximately 25–35% projected by 2030.
Key Takeaways
- The global botulinum toxin market is projected to grow to USD 10 billion by 2030.
- Prices for Botox are currently USD 15–19 per unit in the U.S.
- Biosimilars are expected to accelerate price reductions, leading to a 25–35% decrease in per-unit prices within the next seven years.
- Market growth is driven by expanding indications, especially in emerging markets.
- Competitive landscape consolidates around several major players, with biosimilars increasing price competition.
FAQs
1. What factors influence the price of NDC 00173-0720?
Reimbursement negotiations, biosimilar competition, manufacturing costs, and regulatory policies are primary influences on pricing.
2. How will biosimilar entrants impact the market?
Biosimilars are likely to reduce prices by 20–30%, pressuring originator sales and fostering increased access in emerging markets.
3. What are the primary therapeutic indications for this drug?
Approved indications include chronic migraines, muscle spasticity, hyperhidrosis, and facial wrinkles for cosmetic purposes.
4. Which regions are emerging as key markets?
Asia-Pacific exhibits rapid growth due to increasing healthcare infrastructure and awareness, with China and Japan leading.
5. How might regulatory changes affect future prices?
Stricter biosimilar pathways and reimbursement policies could further lower prices or incentivize innovation and premium pricing based on value.
References
- Fortune Business Insights. (2023). Botulinum Toxin Market Size, Share & Industry Analysis. https://fortuneinsights.com
- U.S. Food and Drug Administration. (2022). Botulinum Toxin (Botox) Approval History. https://fda.gov
- MarketWatch. (2022). Botulinum Toxin Market Trends and Forecasts. https://marketwatch.com
- MediQuality Reports. (2023). Global Biosimilar Impact on Botulinum Toxin. https://mediquality.com
